Non‐HLA AT1R antibodies are highly prevalent after pediatric intestinal transplantation

• Published in: Pediatric transplantation Vol. 25; no. 3; pp. e13987 - n/a
• Main Authors: Chan, Alvin P, Guerra, Marjorie‐Anne R, Rossetti, Maura, Hickey, Michelle J, Venick, Robert S, Marcus, Elizabeth A, McDiarmid, Suzanne V, Farmer, Douglas G, Reed, Elaine F, Wozniak, Laura J
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.05.2021
• Subjects: Adolescent; Angiotensin; Angiotensin II; angiotensin II type‐1 receptor antibody; Antibodies; antibody‐mediated rejection; Autoantibodies - blood; Child; Child, Preschool; Enteritis; Female; Graft rejection; Histocompatibility antigen HLA; HLA Antigens; Humans; Immune response; Intestinal Failure - blood; intestinal transplantation; Intestine; Intestines - transplantation; liver/intestine transplant; Male; non‐HLA antibody; Pathogenicity; Patients; pediatric; Pediatrics; Receptor, Angiotensin, Type 1 - immunology; Retrospective Studies; Transplantation; Transplants & implants; Young Adult; angiotensin II type-1 receptor antibody; intestinal transplantation; non-HLA antibody; liver/intestine transplant; antibody-mediated rejection; pediatric
• ISSN: 1397-3142; 1399-3046
• DOI: 10.1111/petr.13987

The role of angiotensin II type‐1 receptor (AT1R) antibodies in intestinal transplantation (ITx) is unclear. The aims were 1) to identify the prevalence of AT1R antibodies in pediatric ITx, compared to pediatric intestinal failure (IF), and 2) to determine whether AT1R antibodies were associated with graft dysfunction. 46 serum samples from 25 ITx patients (3 isolated ITx, 22 liver‐inclusive ITx) were collected during routine visits >6 months apart and during episodes of graft dysfunction as a result of infectious enteritis or rejection. For comparison, samples were collected from 7 IF control patients. AT1R antibodies were considered positive for levels >17 U/mL. The median (range) AT1R antibody level for ITx patients was 40.0 U/mL (7.2–40.0), compared to 7.0 U/mL (5.7–40.0) for IF patients (p = .02). There was a trend toward higher prevalence of AT1R antibodies in ITx compared with IF patients (68% versus 29%, p = .09). Among ITx patients, the prevalence of AT1R antibodies was not different between periods of active graft dysfunction and normal health (83% versus 67%, p = .31). For 16 patients with >2 samples, AT1R antibodies remained positive in 67% cases, developed in 14% cases, disappeared in 10% cases, and remained negative in 10% cases. The changes in AT1R antibodies did not correlate with de/sensitizing events. This is the first study of AT1R antibodies in pediatric ITx. AT1R antibodies are highly prevalent after ITx and may be triggered by immune activation associated with the transplant. However, their pathogenicity and clinical utility remain in question.